PicoCELA Inc. (NASDAQ:PCLA) Short Interest Down 70.6% in June

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 37,187 shares, a decrease of 70.6% from the May 31st total of 126,693 shares. Currently, 93.0% of the company’s shares are sold short. Based on an average daily volume of 116,946 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent SEC filing.

PicoCELA Price Performance

PCLA opened at $6.97 on Friday. PicoCELA has a 1 year low of $1.35 and a 1 year high of $112.20. The company’s 50 day simple moving average is $4.26 and its 200 day simple moving average is $4.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.13 and a quick ratio of 1.57.

Key Headlines Impacting PicoCELA

Here are the key news stories impacting PicoCELA this week:

• Positive Sentiment: PCLA experienced multiple LULD pauses throughout the day, indicating extreme price swings and very active trading interest. Repeated halts often accompany a sharp momentum move and can attract additional speculative volume. LULD pause trading halts
• Neutral Sentiment: Recent short-interest updates were mixed: one report showed short interest falling sharply in mid-June, while another later filing listed zero shares short. That data is unusual and may reflect limited float or reporting anomalies rather than a clear fundamental catalyst. Short interest updates

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PicoCELA in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, PicoCELA presently has a consensus rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.